Our program is highly competitive. Due to our individualized, hands-on approach to consulting we can accept only a limited number of companies into the GALS program.

Admission Criteria

Applicants must be promising emerging life science companies that have great potential to benefit from the GALS program. Companies must have an affiliation with Germany, i.e. incorporated in Germany or with significant operations there. Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies. The stage of the company’s growth is relevant; the age of the company is not.

Application

The GALS application consists of around 20 questions about your company, team, technology, and business plan. It only takes a couple of hours to complete. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available). Companies apply to the GALS program via the external platform SurveyMonkey.

Deadlines

GALS accepts companies into the program on a rolling basis. Companies can apply any time. Applications are reviewed by the Selection Committee every 6-8 weeks. Program start dates are flexible.

Next application deadline: June 2017 (date to be announced)

Selection Process

The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications. GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology and business strategy.

APPLY NOW

Selection Committee

Marcus Schabacker
Marcus Schabacker

Read Bio
X

Dr. Schabacker currently serves as Corporate Vice President and Chief Scientific Officer at Baxter Healthcare Corporation. In this role, he leads the Research & Development (R&D), Regulatory Affairs, Program Management Office, Global Patient Safety, Medical Affairs, Life Science and Clinical Development organizations for Baxter. He is responsible for driving innovation, enhancing scientific technical and medical capabilities to ensure a strong foundation of safety, clinical development, and regulatory support.

Prior to his appointment as CSO, Dr. Schabacker joined Baxter in March 2011 as the head of R&D for Baxter’s Medical Products business unit. He led the integration of multiple R&D teams into one global organization and placed R&D resources closer to its global customer base, including those in fast- growing emerging markets such as China and India.

Before joining Baxter, Dr. Schabacker held the position of Senior Vice President and Chief Scientific Officer at ConvaTec, Inc. – a leading developer and marketer of medical technologies in ostomy care, wound therapeutics, continence and critical care, and infusion devices. Dr. Schabacker’ s previous roles include Corporate Vice President R&D at B. Braun Medical and Senior Medical Officer at Mafikeng General Hospital, South Africa where he established and led the Anesthesia and Intensive Care Medicine Department and also served as the Medical Lead for Disaster Planning.

Dr. Schabacker has an MD and a Doctorate in anesthesia from Medical University of Lübeck in Germany and certifications in Anesthesiology, Disaster Medicine, and Emergency Medicine.

Thomas Kiessling
Thomas Kiessling

Read Bio
XThomas Kiessling

Member of GALS Advisory Council
Member of GALS Selection Committee

Short Bio

Thomas is a technology entrepreneur with 25 years of experience in product and business development in software, hardware, and online consumer products.

Thomas was the CTO / CIO of Securitas Direct, a Bain Capital & Hellman & Friedman company until the end of 2015. Securitas Direct is a private-equity owned supplier of home alarms and connected services for protected homes, sold to Hellman & Friedman in October 2015. Prior to this position Thomas was Chief Product and Innovation Officer for Deutsche Telekom / T Mobile group.

Thomas has also worked in CTO / product development roles for bwin Interactive Entertainment AG, Amadeus, and GlobalOne HQ, managing growth businesses and bringing transformational change.

Thomas holds an MA in Economics and was a Fulbright Scholar at the American University, Washington D.C. He also earned a Master in Telecommunications Network Engineering in Paris, France before receiving his Ph.D. in Telecommunications Economics from University of Stuttgart, Germany.

Michael Bogenstaetter
Michael Bogenstaetter

Read Bio
XMichael Bogenstaetter

Member of GALS Selection Committee

Short Bio

Michael Bogenstaetter has over 15 years experience in Biopharma R&D and commercialization of innovative therapies having worked in different leadership roles with companies such as Johnson & Johnson, Novartis and Sanofi and having advised leading Biopharma organizations as member of the Health Care practice of The Boston Consulting Group. Currently, Michael is an independent management consultant in the Life Sciences area.

Michael holds a Ph.D. in organic chemistry from University of Munich and a full time MBA from London Business School.

Kirti Patel
Kirti Patel

Read Bio
XKirti Patel

Member of GALS Selection Committee

Short Bio

Kirti Patel is CEO and President, and Executive Board Director at Eppendorf Manufacturing Corporation (EMC), a wholly-owned subsidiary of Eppendorf AG based in Hamburg, Germany. Kirti joined Eppendorf in April, 2013 to accelerate the integration of New Brunswick Operations that Eppendorf acquired in 2008.

Prior to his current role, Kirti was General Manager and VP at Siemens Healthcare – Molecular Imaging Division, with full P&L responsibility for the global Preclinical Solutions business. Over four years, Kirti successfully led the business – maximizing revenue and profit growth by building the right team; creating and executing global sales and market strategies; developing deep customer relationships; launching innovative products; streamlining operations; and establishing a Services business.

Kirti came to Siemens Healthcare in 2005 when Siemens Medical Ultrasound Division acquired Sensant, a company Kirti co-founded in 1998 to drive a fundamental change in 3-dimensional medical ultrasound imaging. After the acquisition, Kirti led the integration of the company into Siemens over a period of two years.

Prior to co-founding Sensant, Kirti worked at Intel for four years in various Engineering and Management positions and was fast-tracked into Intel’s Management Training Program within 18 months of joining.

Kirti holds an MBA from the Wharton Business School, an MS in Electrical Engineering from Stanford University, an MS in Chemical Engineering from University of California at Davis and a BS in Chemical Engineering from Mangalore University in India.

Frank Diehl
Frank Diehl

Read Bio
XFrank Diehl

Member of GALS Selection Committee

Short Bio

Frank Diehl is currently the Chief Scientific Officer of the Sysmex Life Science Business. He led until 2014 the R&D as well as Laboratory Operations of Sysmex Inostics. Before that he co-founded Inostics together with Indivumed as well as colleagues from The Johns Hopkins University and was the Managing Director of Inostics from 2008 to 2013. Frank Diehl has over 10 years of experience in assay development in the field of oncology and genomics.

He obtained his postdoctoral experience at The Johns Hopkins University and the Howard Hughes Medical Institute in Baltimore, Maryland. During this time he focused on the development of DNA-based molecular technologies for the diagnosis of colorectal cancer. Frank Diehl has received several research awards and a numerous peer-reviewed articles. He earned his graduate degree in molecular pathology from the University of Heidelberg and the German Cancer Research Center (DKFZ) in Heidelberg.

Derek Young
Derek Young

Read Bio
XDerek Young

Member of GALS Selection Committee

Short Bio

Derek is an entrepreneur and innovator in the healthcare sector. He is a named inventor of over 30 patents with commercial success globally. Derek has successfully co-founded a number of European medical device startup companies including Medtech, Advanced Surgical Concepts and Haptica before spinning into the Royal College of Surgeons (RCSI) in Dublin. While there Derek established a Healthcare Innovation Hub to develop ideas received from clinicians and inventors in Europe and Internationally.

Derek has spear-headed and completed at least 12 Medical Device Licenses deals with key International Healthcare MNC over the last 12 years, completing deals with companies such as Ethicon Endo Surgery, Johnson & Johnson, Covidien, Boston Scientific and CAE Healthcare.

Derek is Founder, CEO and key promoter of i360medical, which is a direct spin out of the Healthcare Innovation Hub that was converted to a for-profit commercial model with the support of the RCSI. I360medical is a European and US based Healthcare Solutions and Medical Device Innovation Company that provides its services to Global Hospital Systems, the Medical Device industry, and clinical communities.

He has gained significant partners and support, and has built an impressive global network of experienced professionals within the medical device and clinical sectors intending to deliver transformational innovation to commercialization change to the international Hospital Systems, Medical Device Industry and Clinical Community.

Derek has a background in Mechanical Engineering, Surgical Innovation and Business Development from the Austin Waldron and Dublin Institute of Technology in Ireland. He also holds a number of board positions on medical device companies and medical research groups at both a national and international level.

Christoph Lengauer
Christoph Lengauer

Read Bio
XChristoph Lengauer

CEO of German Accelerator Life Sciences

Short Bio

Christoph is executive vice president at Blueprint Medicines (BPMC) in Cambridge, MA. He has a proven record in cancer drug discovery, including contributing to 22 development candidates, 13 drugs or programs that reached first-in-human clinical trials and three approved drugs. He joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, Christoph was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine where he worked with Drs. Bert Vogelstein and Ken Kinzler for more than ten years.

Christoph discovered that all cancers are genetically unstable and was involved in the identification of several oncogenic driver genes. He has authored more than hundred scientific articles published in top-tier scientific journals, including Nature and Science. He is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller “The Immortal Life of Henrietta Lacks.” Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg, Germany and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph has received numerous awards including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and a V Foundation scholarship. He was awarded the Novartis Oncology’s President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.

Christoph is also venture partner at Third Rock Ventures. In fall of 2015 he was appointed by the German Ministry for Economic Affairs & Energy to lead the build out of the German Accelerator Life Sciences in Cambridge.